WO2004032844A3 - Compositions et methodes de traitement de la douleur - Google Patents

Compositions et methodes de traitement de la douleur Download PDF

Info

Publication number
WO2004032844A3
WO2004032844A3 PCT/US2003/031481 US0331481W WO2004032844A3 WO 2004032844 A3 WO2004032844 A3 WO 2004032844A3 US 0331481 W US0331481 W US 0331481W WO 2004032844 A3 WO2004032844 A3 WO 2004032844A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
treating pain
compositions
cox
antagonist
Prior art date
Application number
PCT/US2003/031481
Other languages
English (en)
Other versions
WO2004032844A2 (fr
Inventor
Stephen J Peroutka
Original Assignee
Synergia Pharma Inc
Stephen J Peroutka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synergia Pharma Inc, Stephen J Peroutka filed Critical Synergia Pharma Inc
Priority to AU2003275433A priority Critical patent/AU2003275433A1/en
Publication of WO2004032844A2 publication Critical patent/WO2004032844A2/fr
Publication of WO2004032844A3 publication Critical patent/WO2004032844A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des méthodes de traitement de la douleur chez un sujet nécessitant ce traitement. Ces méthodes consistent à administrer des doses efficaces de précurseur de noradrénaline ('NE') et un antagoniste de prostaglandine ('PG'). Un précurseur NE peut être une thréo-3-(3,4 dihydroxyphényl)sérine, un dérivé de celui-ci, ou un sel pharmaceutiquement acceptable de celui-ci. Un antagoniste PG peut être un inhibiteur de cyclooxygénase (par exemple, COX-1 ou COX-2).
PCT/US2003/031481 2002-10-07 2003-10-06 Compositions et methodes de traitement de la douleur WO2004032844A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003275433A AU2003275433A1 (en) 2002-10-07 2003-10-06 Compositions and methods for treating pain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41626802P 2002-10-07 2002-10-07
US60/416,268 2002-10-07

Publications (2)

Publication Number Publication Date
WO2004032844A2 WO2004032844A2 (fr) 2004-04-22
WO2004032844A3 true WO2004032844A3 (fr) 2004-10-21

Family

ID=32093834

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/031481 WO2004032844A2 (fr) 2002-10-07 2003-10-06 Compositions et methodes de traitement de la douleur

Country Status (2)

Country Link
AU (1) AU2003275433A1 (fr)
WO (1) WO2004032844A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158149B2 (en) 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
US20060105036A1 (en) 2003-05-12 2006-05-18 Stephen Peroutka Threo-dops controlled release formulation
CA2580694A1 (fr) * 2004-09-23 2006-03-30 Alexander Michalow Methodes permettant de reguler les systemes de neurotransmetteurs en induisant des contre-adaptations
JP2010520885A (ja) * 2007-03-09 2010-06-17 チェルシー・セラピューティクス，インコーポレイテッド 線維筋痛症の治療のためのドロキシドパ及びその医薬組成物
US8383681B2 (en) 2007-05-07 2013-02-26 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders or attention deficit disorders
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616618A (en) * 1993-01-29 1997-04-01 Sumitomo Pharmaceuticals Company, Limited Threo-3-(3,4-dihydroxyphenyl)serine analgesic composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616618A (en) * 1993-01-29 1997-04-01 Sumitomo Pharmaceuticals Company, Limited Threo-3-(3,4-dihydroxyphenyl)serine analgesic composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KATZUNG B.G.: "Basic & Clinical Pharmacology", A LANGE MEDICAL BOOK, vol. 6TH ED., 1995, pages 312 - 314, XP002951274 *

Also Published As

Publication number Publication date
WO2004032844A2 (fr) 2004-04-22
AU2003275433A1 (en) 2004-05-04
AU2003275433A8 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
EP1485381B8 (fr) Azolylaminoazines en tant qu'inhibiteurs de proteines kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
WO2004087699A3 (fr) Thiazoles utiles en tant qu'inhibiteurs des proteines kinases
WO2004087698A3 (fr) Thiazoles utiles en tant qu'inhibiteurs de proteines kinases
WO2005105780A3 (fr) Compositions utiles en tant qu'inhibiteurs de la rock et d'autres proteines kinases
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
WO2004078712A3 (fr) Derives d'isoquinoline et leurs methodes d'utilisation
WO2004046120A3 (fr) Diaminotriazoles convenant comme inhibiteurs de proteine kinases
MXPA05008172A (es) Derivados de malonamida como inhibidores gamma-secretasa.
TW200420549A (en) Thiazole derivatives
SG179418A1 (en) Inhibitors of the hedgehog pathway
WO2002036562A3 (fr) 1-aryl- ou 1-alkylsulfonyl-heterocyclylbenzazoles en tant que ligands de 5-hydroxytryptamine-6
BR0215898A (pt) Composição e método para a formação não permanente durável de pelo menos uma fibra queratìnica ou para a retenção durável de uma forma não permanente de pelo menos uma fibra queratìnica e kit para proteger pelo menos uma fibra queratìnica contra danos extrìnsecos
AU2003267203A1 (en) Method for administering thermotherapy to prevent the growth of tumors
AUPR177300A0 (en) Therapeutic methods
WO2005030753A3 (fr) Agents therapeutiques utiles pour traiter la douleur
WO2005016261A3 (fr) Sels de pamoate d'aripiprazole et d'haloperidol
IL192100A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
WO2005030766A8 (fr) Composes phenyl-carboxamide utiles pour traiter la douleur
WO2007002836A3 (fr) Procedes et compositions pour la prevention et le traitement de maladie renale
CA2668320A1 (fr) Utilisation de 3-alpha-androstanediol, eventuellement en combinaison avec un agoniste 5-ht1a, dans le traitement du dysfonctionnement sexuel
WO2007058989A3 (fr) Quinazolines utiles en tant que modulateurs de canaux ioniques potentio-dependants
WO2004047792A3 (fr) Glucocorticoides liposomaux
WO2002051832A3 (fr) Composes heterocyclylalkylindole ou azaindole comme ligands 5-hydroxytryptamine-6

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP